Canada markets close in 2 hours 2 minutes
  • S&P/TSX

    19,229.68
    -28.64 (-0.15%)
     
  • S&P 500

    3,847.01
    -53.10 (-1.36%)
     
  • DOW

    31,152.28
    -285.98 (-0.91%)
     
  • CAD/USD

    0.7780
    +0.0012 (+0.15%)
     
  • CRUDE OIL

    111.58
    +2.01 (+1.83%)
     
  • BTC-CAD

    26,521.21
    -270.18 (-1.01%)
     
  • CMC Crypto 200

    448.50
    -1.56 (-0.35%)
     
  • GOLD FUTURES

    1,821.20
    -3.60 (-0.20%)
     
  • RUSSELL 2000

    1,748.40
    -23.35 (-1.32%)
     
  • 10-Yr Bond

    3.2000
    +0.0060 (+0.19%)
     
  • NASDAQ

    11,264.73
    -259.82 (-2.25%)
     
  • VOLATILITY

    27.96
    +1.01 (+3.75%)
     
  • FTSE

    7,323.41
    +65.09 (+0.90%)
     
  • NIKKEI 225

    27,049.47
    +178.20 (+0.66%)
     
  • CAD/EUR

    0.7383
    +0.0047 (+0.64%)
     

This Dividend Stock Just Made a Very Bullish Crossover

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

When dividend stocks are on the rise, it could be time to buy them up. That's because an increase in the share price will result in a declining yield. Plus, buying before it takes off could allow investors to benefit from the potential gains earned on a rising stock, which can complement the cash flow generated from its recurring dividend payments.

That's where healthcare stock Becton, Dickinson (NYSE:BDX) finds itself in today. Its yield of 1.3% is in line with the S&P 500 average and can be a good source of regular cash flow for investors. And of late, the stock has been picking up some momentum. Earlier this month, it made a bullish crossover with its 50-day moving average climbing higher than its 200 day average. When that happens, that has the potential to trigger more momentum buying.

It could also be a sign of more optimism behind the medical device company, which could see better results ahead if there's a return to normalcy in the healthcare industry – assuming, of course, that the omicron variant doesn't derail that.

Read:

The company is coming off an already strong quarter where for the period ending Sept. 30, 2021, its sales of $5.1 billion rose 7.3% year over year. And with expenses remaining fairly consistent, that allowed the company's bottom line to see a large 136% improvement in its earnings per share, which rose from $0.36 to $0.85. If it can build on those results, this could be an underrated dividend stock to own this year.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting